Loading…
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-172M | $-166M | $-113M | -212.2% | - | - |
| 2024 | $0M | $-91M | $-81M | $-71M | -46.9% | - | - |
| 2023 | $0M | $-41M | $-37M | $-34M | -45.2% | - | - |
| 2022 | $0M | $-36M | $-35M | $-28M | -31.9% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 36.53 | 41.76 | 90.89 | 172.50 |
| Operating Income | -36.53 | -41.76 | -90.89 | -172.50 |
| EBITDA | -36.21 | -41.45 | -90.57 | -172.15 |
| EBIT | -36.53 | -41.76 | -90.89 | -172.50 |
| Pretax Income | -35.35 | -36.95 | -80.60 | -165.67 |
| Net Income | -35.35 | -36.95 | -80.60 | -165.67 |
| Net Income Common Stockholders | -35.35 | -36.95 | -80.60 | -165.67 |
| Total Expenses | 36.53 | 41.76 | 90.89 | 172.50 |
| Research And Development | 24.25 | 27.67 | 73.28 | 154.22 |
| Selling General And Administration | 12.28 | 14.09 | 17.61 | 18.27 |
| Normalized EBITDA | -36.21 | -41.45 | -90.57 | -172.15 |
| Normalized Income | -35.35 | -36.95 | -80.60 | -165.67 |
| Basic EPS | -1.37 | -0.84 | -1.32 | -2.27 |
| Diluted EPS | -1.37 | -0.84 | -1.32 | -2.27 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -35.35 | -36.95 | -80.60 | -165.67 |
| Reconciled Depreciation | 0.32 | 0.31 | 0.32 | 0.35 |
| Net Income From Continuing And Discontinued Operation | -35.35 | -36.95 | -80.60 | -165.67 |
| Total Operating Income As Reported | -36.53 | -41.76 | -90.89 | -172.50 |
| Diluted Average Shares | 25.76 | 43.90 | 61.26 | 72.95 |
| Basic Average Shares | 25.76 | 43.90 | 61.26 | 72.95 |
| Diluted NI Availto Com Stockholders | -35.35 | -36.95 | -80.60 | -165.67 |
| Net Income Including Noncontrolling Interests | -35.35 | -36.95 | -80.60 | -165.67 |
| Net Income Continuous Operations | -35.35 | -36.95 | -80.60 | -165.67 |
| Other Income Expense | 1.17 | 4.81 | 10.29 | 6.82 |
| Other Non Operating Income Expenses | 1.17 | 4.81 | 10.29 | 6.82 |
| General And Administrative Expense | 12.28 | 14.09 | 17.61 | 18.27 |
| Other Gand A | 12.28 | 14.09 | 17.61 | 18.27 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Larimar Therapeutics, Inc.this co. | LRMR | $451M | - | 4.62 | -212.2% | -1.85 |
| 4D Molecular Therapeutics, Inc. | FDMT | $461M | - | 1.00 | -27.7% | -0.45 |
| MiMedx Group, Inc. | MDXG | $458M | 9.64 | 1.78 | 18.9% | 4.00 |
| Pacific Biosciences of California, Inc. | PACB | $456M | - | 81.67 | -10214.5% | -5.12 |
| Candel Therapeutics, Inc. | CADL |
| $453M |
| - |
| 6.53 |
| -73.5% |
| -8.07 |
| Perspective Therapeutics, Inc. | CATX | $448M | - | 1.41 | -49.8% | -2.78 |
| Myriad Genetics, Inc. | MYGN | $442M | - | 1.19 | -99.4% | -2.56 |
| Beta Bionics, Inc. | BBNX | $441M | - | 1.63 | -25.5% | -3.29 |
| AngioDynamics, Inc. | ANGO | $440M | - | 2.56 | -18.6% | -634.17 |
| Peer Median | - | 9.64 | 1.70 | -38.8% | -3.04 | |